We had solved that single molecule signal ... landmark NGS papers in November 2008—the first African genome, the first Asian genome, and the first cancer genome—all featuring the Illumina ...

This is why we partnered with Illumina, the leading NGS provider, integrating our DNA ... grew double digits year-over-year, a strong signal of a broadening adoption. As we roll out additional ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN stock.

The import ban on Illumina's NGS sequencers follows its placement on China's Ministry of Commerce's (MOFCOM) ‘Unreliable Entity List’ last month. Image credit: JHVEPhoto via Shutterstock.

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

which is expected to directly compete with Illumina’s next-generation sequencing (NGS) portfolio. Roche’s management has expressed confidence that SBX can produce data comparable to NGS ...

Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...

GlobalData’s senior medical analyst says the ban will add to a downward trend for Illumina in the Chinese market.

"It's exciting to see, through our customers' results, how Callisto Apps are helping clinical labs with consistent and cost-efficient whole genome sequencing with Illumina and PacBio. Callisto is ...